Company intelligence / Profile preview

Tensegrity Pharma

Chuo-ku, Tokyo, Japandnb.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Developing TSP-101, a novel anti-Fn14 fully human monoclonal antibody that can antagonize Fn14-TWEAK signaling. Expected to have anti-cachexia effects by blocking signaling of specific factors overexpressed in various cancers with high cachexia incidence and suppressing cancer-derived inflammatory responses, as well as anticancer effects by improving the tumor microenvironment

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (fully human monoclonal antibody)
Industry: Biotech

Drug pipeline

3 assets

ARGX-101

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Astellas Pharma Inc. (took over a strategic discontinued project)

Beyond the preview

Go deeper on Tensegrity Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tensegrity Pharma.

Explore the full profile